Compare Charles River Laboratories Intl. Inc (CRL) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Hyatt Hotels Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Hyatt Hotels Corporation trades at $160.27 (market cap $15.02B). The key difference: Charles River Laboratories Intl. Inc and Hyatt Hotels Corporation are close in size by market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Hyatt Hotels Corporation for 148 Days on average.
| CRL | H | |
|---|---|---|
Market Cap | $14.23B | $15.02B |
Volume | 1,176,885 | 842,340 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $202.09 |
52-Week Low | $149.93 | $135.42 |
Typical Hold Time | 33 Days | 148 Days |
Enterprise Value | $17.06B | $18.93B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
Hyatt Hotels (H) trades at $157.14, down 1.24% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows mixed fundamentals: revenue grew to $7.10B in 2025, but net income was a loss of $52M, and valuation ratios like a P/E of 194 appear elevated. Recent news highlights expansion efforts, including a loyalty collaboration with Delta Air Lines and new hotel openings, signaling growth initiatives amid operational challenges.
The outlook for H is cautious; analyst consensus is a Moderate Buy with a $197.77 price target, but high debt levels and volatile profitability pose risks. Upside depends on sustained revenue growth and margin improvement, while downside risks include economic sensitivity and execution delays in new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
